ArticleBMC psychiatry2026
An exploratory study on the impact of medication usage patterns on relapse among community schizophrenia patients.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundRelapse is highly prevalent among individuals with schizophrenia, imposing a significant burden on public health systems and patients. Medication usage patterns, encompassing both prescription and usage behaviors, are critical for ensuring adherence to antipsychotic medication and controlling relapse. However, the impact of these patterns on relapse dynamics remains understudied, particularly within primary mental health care settings where data limitations such as panel-count data exist.
methodsData were sourced from the Basic Data Collection and Analysis System for Severe Mental Disorders in Western China, enrolling 7,137 community-based newly diagnosed schizophrenia patients under management from 2019 to 2022. The exposure factor was medication usage patterns, defined by three variables: number of drug types, drug dosage, and medication adherence behaviors. The outcome was recurrence, with readmission serving as a surrogate indicator for recurrence in this study.
methodsMultivariate longitudinal data clustering of medication patterns was performed using Markov Chain Monte Carlo (MCMC)-based generalized linear mixed models. Adjustments were made for the minimal covariate set identified via a directed acyclic graph (DAG) constructed through systematic literature review and expert consultation, employing inverse probability weighting. The association between medication patterns and relapse was estimated semiparametrically using accelerated mean models.
resultsAmong 7,137 schizophrenia patients, 1,633 experienced relapse, yielding a relapse rate of 22.88%. Four medication usage patterns were identified: 5067 patients (71%) belonged to the "standard treatment group," 677 patients (9.49%) to the "monotherapy group," 826 patients (11.57%) to the "inadequate treatment group," and 567 patients (7.94%) to the "overdose group." Inadequate treatment and non-standard medication practices were associated with increased relapse risk.
conclusionAlthough most community schizophrenia patients adhere to standard medication patterns, a significant proportion receive insufficient antipsychotic treatment. Inadequate treatment and non-standard medication practices elevate relapse risk, underscoring the necessity for primary mental health institutions to implement comprehensive interventions targeting these patients. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
42449290What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.